OncoMatch/Clinical Trials/NCT02535221
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Is NCT02535221 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Goserelin+TAM+AI and Epirubicin+CTX+5-Fu for breast cancer.
Treatment: Goserelin+TAM+AI · Epirubicin+CTX+5-Fu — This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 ER positive (>50% cell in IHC) (>50% cell in IHC)
Histologically confirmed HR+ (ER or PR positive, and >50% cell in IHC)
Required: PR (PGR) PR positive (>50% cell in IHC) (>50% cell in IHC)
Histologically confirmed HR+ (ER or PR positive, and >50% cell in IHC)
Required: HER2 (ERBB2) negative
HER2 negative breast cancer by pathological evaluation
Disease stage
Required: Stage T2N0M0 (TNM)
Excluded: Stage LYMPH NODE POSITIVE
Stage: T2N0M0(cT>2cm, SLNB negative), hard to proceed the breast conserving surgery(not feasible or may affect the appearance of breast)
Demographics
Prior therapy
Cannot have received: anti-tumor treatment
No other previous treatment for primary breast cancer; have been attendance in other anti-tumor treatment or other clinical trials
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02535221 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ESR1?
Yes, ESR1 ER positive (>50% cell in IHC) is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR PR positive (>50% cell in IHC) is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage T2N0M0 is required.
Is there an age limit?
Yes. Patients must be 55 years or younger and at least 35 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify